Clinical trials: Advanced Clear Cell Renal Cell Carcinoma
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Advanced Renal Cell Carcinoma, Advanced Melanoma
Sitagliptin With Pembro in RCC and Melanoma
This study is testing whether adding the drug sitagliptin to the standard immunotherapy pembrolizumab is safe and may help people with advanced melanoma or advanced renal cell carcinoma (kidney cancer) whose cancer has stopped…
- Trial name
- NCT07634380
- Testing
- Sitagliptin, Pembrolizumab
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Fernando Maciel Barbosa
Urothelial Carcinoma, Renal Cell Carcinoma
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
The objective of this study is to assess the overall response rate, evaluate the antitumor activity, and characterize the safety and tolerability of BGB-A445 alone or in combination with tislelizumab in participants With Advanced…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma
- Trial name
- NCT05661955
- Testing
- BGB-A445, Tislelizumab
- Where
- 18 sites in China
- Volunteers
- 113 people
- Sponsor
- BeiGene
Advanced Malignant Neoplasm, Advanced Melanoma
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
This trial studies the genetic analysis of blood and tissue samples from patients with cancer that has spread to other anatomic sites (advanced) or is no longer responding to treatment.
- Conditions
- Advanced Malignant Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03707574
- Testing
- Biospecimen Collection
- Where
- 144 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Carcinoma, Renal Cell, Melanoma
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GC1008, a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in previously treated patients with…
- Trial name
- NCT00356460
- Testing
- GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody, GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Genzyme, a Sanofi Company
Advanced Renal Cell Carcinoma (aRCC)
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
This study will collect real-world data for the new treatment pathways for all patients with Advanced Renal Cell Carcinoma (ARCC) who were treated with a 1L IO (first-line, Immuno-Oncology checkpoint inhibitor) combination…
- Trial name
- CARINA (NCT04957160)
- Where
- 9 sites in United Kingdom
- Volunteers
- 281 people
- Sponsor
- Ipsen
Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
The goal of this clinical trial is to learn about the safety and preliminary antitumor activity of zanzalintinib in combination with AB521 (doublet) and in combination with AB521 plus nivolumab (triplet) in participants with…
- Trial name
- NCT06191796
- Testing
- zanzalintinib, AB521, Nivolumab
- Where
- 14 sites in United States
- Volunteers
- 25 people
- Sponsor
- Exelixis
Kidney Cancer
Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with stage III…
- Trial name
- NCT00003551
- Testing
- aminocamptothecin colloidal dispersion
- Where
- 2 sites in United States
- Sponsor
- Emory University
CD70-positive Advanced Renal Clear Cell Carcinoma
UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of UCL70805F in patients with CD70-positive advanced renal clear cell carcinoma.
- Trial name
- NCT07500805
- Testing
- UCL70805F
- Where
- China
- Volunteers
- 21 people
- Sponsor
- UTC Therapeutics Inc.
Kidney Cancer
Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
RATIONALE: Biological therapies, such as interferon alfa-2b, may interfere with the growth of tumor cells. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor.
- Trial name
- NCT00072046
- Testing
- bevacizumab, recombinant interferon alfa
- Where
- 493 sites in United States, Canada
- Volunteers
- 732 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Advanced or Metastatic Renal Cell Carcinoma
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after…
- Trial name
- CaboPoint (NCT03945773)
- Testing
- Cabozantinib
- Where
- 40 sites in Austria, France and 5 more
- Volunteers
- 127 people
- Sponsor
- Ipsen
Clear Cell Renal Cell Carcinoma
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
The purpose of the study is to test different doses of X4P-001 given alone and in combination with axitinib in participants diagnosed with advanced renal cell carcinoma.
- Trial name
- NCT02667886
- Testing
- X4P-001, axitinib
- Where
- 20 sites in United States, South Korea
- Volunteers
- 74 people
- Sponsor
- X4 Pharmaceuticals
Metastatic Renal Cell Carcinoma
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases
Evaluate the efficacy and tolerability of sorafenib in RCC patients underwent to metastasectomy
- Trial name
- NCT01444807
- Testing
- sorafenib
- Where
- 14 sites in Italy
- Volunteers
- 132 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Renal Cell Carcinoma
PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
Reported in the 2018 NEJM (378; 1277) article, the combination of checkpoint inhibitors ipilimumab (anti-CTLA-4 antibody) and nivolumab (anti-PD-1 antibody) phase III trial Checkmate 214 demonstrated statistically significant…
- Trial name
- PIVOT-RCC (NCT03598816)
- Testing
- Durvalumab, Tremelimumab, TDS-IM v1.0 System
- Sponsor
- Washington University School of Medicine
Renal Cell Carcinoma
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
The purpose of this study is to assess the safety and efficacy of monotherapy pembrolizumab (MK-3475) in participants with renal cell carcinoma (RCC).
- Trial name
- NCT02853344
- Testing
- Pembrolizumab
- Volunteers
- 275 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Solid Tumour, Renal Cell Carcinoma
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
This phase I trial studies the side effects and best dose of giving vorinostat and sorafenib tosylate together in treating patients with kidney or non-small cell lung cancer.
- Conditions
- Malignant Solid Tumour, Renal Cell Carcinoma, Non Small Cell Lung Carcinoma
- Trial name
- NCT00635791
- Testing
- Sorafenib, Vorinostat
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Colorado, Denver
Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC)
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC.
- Conditions
- Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer, Renal Cancer
- Trial name
- NCT03634540
- Testing
- Belzutifan, Cabozantinib
- Where
- 10 sites in United States
- Volunteers
- 118 people
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Oncology, Solid Tumor
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma).
- Conditions
- Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03637803
- Testing
- MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
- Where
- 5 sites in United States
- Volunteers
- 63 people
- Sponsor
- 4D pharma plc
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
This phase I/II trial studies the side effects of sitravatinib and how well it works with nivolumab in treating patients with kidney cancer that has spread to other places in the body.
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT03015740
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center